Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
NCT04076228
·
clinicaltrials.gov ↗
COMPLETED
Status
37
Enrollment
OTHER
Sponsor class
Conditions
NSCLC Stage IV
Interventions
DRUG:
Pembrolizumab
Sponsor
Kiang Wu Hospital